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The present dissertation has the goal of providing an overview of the community pharmacy 
sector in Portugal, its evolution and future tendencies and strategies to adopt.   
Being a segment extremely regulated by the State, during the past years, the community 
pharmacy sector faced major changes that forced an alteration in the vision and strategy of 
these organizations.  
In order to understand this progress, a literature review addressing the outline of the 
healthcare sector in Portugal is presented; main alterations in the community pharmacy 
sector and its current situation and the strategies to take into consideration in the shape of 
this segment´s future are also considered. To sustain this research, the case of Grupo Holon, 
a network of independent pharmacies that operate under the same image and brand and that 
introduced in the market an innovative approach to counter the negative path of this sector, 
is shown.  
Finally, teaching notes are provided with explanatory learning objectives and proposed 













Título da Tese: A Evolução da Farmácia Comunitária em Portugal 
Subtítulo da Tese: O Caso do Grupo Holon 
Autora: Bárbara Ramos Ferreira 
A presente dissertação tem como objetivo fornecer uma visão geral sobre o sector da 
farmácia comunitária em Portugal, a sua evolução e tendências futuras. 
Sendo um segmento extremamente regulado pelo Estado, ao longo dos anos a farmácia 
comunitária presenciou diversas mudanças que forçaram a alteração da visão e estratégia 
destas organizações.  
Com o intuito de compreender este processo, é apresentada uma revisão de literatura que 
aborda os contornos do sector da saúde em Portugal, as principais alterações na farmácia 
comunitária e a sua atual situação, bem como as estratégias a ter em consideração no molde 
futuro deste mercado. Para sustentar esta pesquisa, é apresentado o caso do Grupo Holon, 
uma rede nacional de farmácias independentes que operam segundo a mesma imagem e 
marca, e que veio introduzir no mercado uma inovadora abordagem que visa contrariar os 
contornos negativos que têm vindo a delinear este sector.   
Finalmente, são fornecidas notas para discussão do caso com explicação dos respetivos 
objetivos de aprendizagem e propostas de questões para aborda-lo como material de estudo, 
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Chapter 1 - Introduction 
The present dissertation aims to analyse the community pharmacy sector in Portugal and 
its future path, using the case of Grupo Holon as a basis to support this analysis and as 
teaching material. 
In order to achieve that purpose, this dissertation addresses the following research 
questions: 
 (RQ1) – Which factors contributed to the current situation of community 
pharmacies in Portugal? 
 (RQ2) - What is the future path/strategy of the sector? 
This study is structured in four different parts: Literature Review (Chapter 2), Case Study 
(Chapter 3), Teaching Notes (Chapter 4) and Conclusions, Limitations and Future Research 
(Chapter 5).  
In the Literature Review section, the reader can access an overview about the evolution of 
the healthcare sector in Portugal and more precisely about the community pharmacy and 
importance of the pharmacist nowadays. The reader can also access information about the 
tendencies and strategies for the future. 
Through the Case Study the reader gains knowledge about Grupo Holon and its activities, 
value proposition and future objectives. 
In the Teaching Notes section, the reader is presented with the learning objectives of this 
research as well as questions that have the goal of deepen the knowledge about the subject.  
Finally, in the last section is presented the conclusion of the entire research as well as 









Chapter 2 - Literature Review 
2.1 - The Healthcare Sector 
In order to understand the community pharmacy sector it is crucial to understand the 
healthcare and pharmaceutical sector since they are intrinsically linked. The community 
pharmacy is a part of the healthcare system and, therefore, represents a part of the 
expenditures on health in the country. 
The expenditures on health in Portugal have been representing, on average, 9.3% of the 
country´s GDP. Since 2009, this value has been decreasing, showing a reverse in the 
tendency verified in the previous years (OECD Health Statistics, 2015) (Figure 1). 
 
Figure 1: Current expenditure on health in Portugal, % of gross domestic product 
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When compared with other European realities, Portugal presents values of expenditure 
similar to the ones practiced in other countries (OECD Health Statistics, 2015) (Figure 2). 
Figure 2: Current expenditure on health, % of gross domestic product 
 
Source: OECD Health Statistics 2015 
Analysing the expenditure on health per capita, it is observable an increase when compared 
to the year 2005. However, as the percentage of GDP, since 2010 this value has been 
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Figure 3: Current expenditure on health in Portugal, per capita in Euros 
 
Source: OECD Health Statistics 2015 
Looking closer to the pharmaceutical market, since 2006 the expenditures in 
pharmaceutical and other non-durables in Portugal have been decreasing. In 2006 the 
expenses on these goods represented 22.6% of the total expenditure on health, however, in 
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Figure 4: Current expenditure on pharmaceuticals and other medical non-durables 
in Portugal, % of current expenditure on health 
 
Source: OECD Health Statistics 2015 
In 2014 the value of the total pharmaceutical market in the country was 3429M euros which 
presents a decrease of 918M euros, expressing a shrinkage of 21.1% (INFARMED, 2014) 
(Figure 5). 
Figure 5: Evolution of Pharmaceutical Market in value (RP), millions of Euros 
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This market is divided in ambulatory market, which stands for the market of all medicines 
(PM and NPM) sold in the community pharmacy and in authorized selling points, and 
hospital market (Tribunal de Contas, 2011).  
Both components of the total value show different behaviours. While the hospital market 
shows a quite steady position, presenting an increase during the years 2011 and 2012, and 
after a small decrease, the ambulatory market presents a reduction of 27.2%, which is 
mainly a consequence of the decrease in the PM market (INFARMED, 2014) (Figure 6). 
 
Figure 6: Evolution of Market Value (RP), millions of Euros 
 
Source: INFARMED, 2014 
Since 2009 the PM market dropped 29% in value based on the PR. Nevertheless, the market 
in volume just decreased 5,5%, showing a big disparity between both levels. (INFARMED, 
2014) (Figure 7). This gap between the values is the reflection of the price reduction policy 
in the medicines that has been ocurring during the past years, leading to a large decreases 
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Figure 7: Evolution of Prescription Medicines sales in value and volume, millions of 
Euros 
 
Source: INFARMED 2014 
The situation in the NPM market is different, since this segment increased 8.2% until 2013, 
presenting a slightly decrease in the year of 2014 in terms of value based in the RP. In 
terms of volume the values present a steady rate, with just slighty changes, being the 
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Figure 8: Evolution of Non Prescription Medicines sales in value and volume, millions 
of Euros 
 
Source: INFARMED 2014 
 
2.2 - Community Pharmacy 
Community pharmacy is an establishment open to the public with the goal of providing 
health care activities to the community related with medicines and the patient (OF, 2009). 
Considering the proximity to the general public, the community pharmacy is often the first 
place visited by the patient when needing some health advice, being this way an entry door 
to the NHS (OF, 2009). It is also the most visited place in the context of health units, 
receiving a normal citizen, on average, two to three times a month (Aguiar, 2007). 
The community pharmacy, although being a private institution, is heavily regulated by 
specific legislation, being INFARMED the entity responsible for supervision in order to 
ensure free access to medicines with equality and safety. 
Nowadays, the community pharmacy in Portugal is one of the pillars of NHS and 
contributes for maximization in health gains, as well as an improvement in patients’ quality 
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Regarding the evolution of these establishments, the number of pharmacies in Portugal has 
been increasing during the past years. In 2008 the number of community pharmacies in the 
country was 2811, increasing to 2934 in 2015. This evolution represents the creation of 
123 new pharmacies, denoting a 4.4% growth in the business (ANF, 2015). 
Figure 9: Evolution of the number of pharmacies in Portugal
 
Source: ANF 2015 
Besides adding economic value to the country, community pharmacies promote de 
development, especially in rural areas and in the interior of the country, where in the 
majority of the times they are the only health service available to the population (Cordeiro, 
2012). This way, they represent an important pillar to the economy of the country and a 
relevant source of development. 
 
2.2.1 - The Pharmacist: 
The pharmacist is the medicine specialist (Cordeiro, 2012) and it is considered to be the 
most accessible health professional to the public (WHO, 1994).  
The functions assumed by these professionals in the Portuguese society go far beyond the 
simply supply of medicines. Due to their background, they are able to provide professional 
advice to their clients about the usage of medicines and medical supplies, drug interactions, 


























•Offers diagnosis and treatment of minor ailments and injuries
Clinical Skills
•Many adults are likely to seek advice from a pharmacist when 
they get sick
•Pharmacy is considered a step up from self-care and a step 
away from visiting the GP
•Patients want more primary care services, health screenings 
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2.2.2 - The Customer 
The changes that occur in the population reflect the changes in the community pharmacy´s 
customer. Therefore, these ones are relevant to understand the business counters.  
In 2014 Portugal had a population of 10.401 million and an aging index (number of elderly 
people for each 100 young people) of 138.6. In 2005 this index presented a value of 108.5, 
demonstrating the increase in aging population that took place during the former years in 
the country (INE, PORDATA, 2015). According to INE statistics, during the following 
years the tendency will be to develop a more aged population (Annex 1). 
In 2014 the number of residents who were more than 65 years old was 2.087.505, 
representing 20% of the total population (INE, PORDATA, 2015). On average, each person 
who is more than 65 years old takes 7.3 medicines per day and 22% of them present 
problems with their usage (ANF, 2009) 
Besides the aging population, also the average household disposable income of a 
Portuguese family has been presenting a decrease since 2009, leading to a deterioration of 
purchasing power (INE, PORDATA, 2016) (Figure 13).  















2.2.3 - Changes in the Sector 
2.2.3.1 - Sale of NPM outside of pharmacies 
During the past ten years, there were several changes in the community pharmacy sector 
in Portugal that modified the outlines of this activity in the country. 
On the 16 of August of 2005, it was approved the commercialization of non-reimbursed 
NPM outside of pharmacies, in places authorized by INFARMED. The government 
claimed that the consumers would benefit from this measure in terms of increase of selling 
points, which would represent easiness in accessibility, as well as benefits regarding price 
(Health Ministry, DL 134/2005, 16 de Agosto 2005). 
Before this date, the price fixation system to the wholesaler was free with only maximum 
commercialization margins stipulated. Therefore, this measure had the purpose of inducing 
a price reduction of NPM, liberalizing its fixation and promoting the competition among 
different channels of distribution and commercialization (Health Ministry, DL 134/2005, 
16 de Agosto 2005). 
In 2007, a new law is published with the goal of amplify the measures stipulated by the DL 
134/2005. After the publication of the first DL, around four hundred new selling points of 
NPM were created in the country, allowing an increase in employment. According to 
INFARMED, this measure allowed, as well, a decrease in the price of the medicines as 
intended (Health Ministry, DL 238/2007, 19 de Junho 2007). 
In the eyes of the Government, all the objectives were achieved which led to a decision of 
amplify the number of medicines that have the classification of NPM, following the steps 
of other European countries.  
Therefore, reimbursed NPM are allowed to be commercialized outside of pharmacies 
without the NHS reimbursement (Health Ministry, DL 238/2007, 19 de Junho 2007). 
This created a new competitive environment to the Portuguese pharmacy scenario since the 
number of drug stores selling NPM increased from 598 sites in 2007 to 1010 sites in 2014, 





Figure 14: Evolution of the number of NPM selling points in Portugal 
 
Source: INFARMED 2014 
 
These new measures also allow the direct competition of large commercial surfaces that, 
due to their size, are able to achieve economies of scale in the commercialization of health 
and wellness products.  
2.2.3.2 - Property Liberalization 
In 2007 occurs more modifications in the sector that result in a new legal regime for the 
community pharmacy. One of the main alterations that this regime brought, was the end of 
exclusive pharmacy ownership by pharmacists, also known as property liberalization. With 
this regulation, any singular person or commercial society, with the exceptions stipulated 
by law, are free to acquire, explore or manage a maximum of four pharmacies. However, 
the technical direction of a pharmacy must be done by a technical pharmacist director in 
permanence and exclusiveness, and it is also required the presence of one more pharmacist 
(OF, 2007). 
This measure permits to balance the free access to property and avoid concentration 
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It should be also known that the autonomous role of the technical pharmacist director earns 
more relevance due to the dissociation between pharmacy property and ownership by 
pharmacist (Alves, 2010). 
This new measure was highly contested by OF and ANF that claimed that there was no 
technical or scientific evidence and was also a contradiction to the existent reality in the 
majority of European countries. Other countries as France, Spain, Italy, Germany and 
Austria assumed an uncompromising position in giving up the exclusive property of 
pharmacies by the pharmacist considering that this was the best measure to protect the 
interest of patients and public health in their own countries (OF, 2007). 
2.2.3.3 - Reduction of Medicine`s price 
Another major change that this sector faced, was the progressive reduction of the selling 
price of medicines.  
It is known that the medicines are the second most consumed goods by the population, just 
preceded by food (Aguiar, 2007). They are the sustenance of a typical pharmacy and their 
sale is extremely important for the healthy function of this business.  
According to a study conducted by Ernest&Young (2011), in a typical Portuguese 
pharmacy, the sale of medicines represent on average 87% of sales and 81% of this value 
represents reimbursed medicines.  
During the past years, the drug politics had been focused mainly in the reduction of prices, 
by administrative cuts or the introduction of the current reimbursement model, plus the 
voluntary reductions of the pharmaceutical industry forced by the instituted competitive 
system (OF, 2012) 
During the former years, it has been observed a constant decrease in the price of medicines. 
Since 2010 the average global RP decreased 23.5%, which results essentially from the price 
decrease of GM that since the same here already dropped 50.6%. The price of branded 






Figure 15: Evolution of the average price of medicines in Portugal, in the Total 
Market 
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Average global RP 13,2 12,42 10,79 10,11 10,1
Average RP GM 13,73 10,43 7,14 6,73 6,78
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In the table below is showed the successive administrative measures taken to reduce the 
price of medicines.  
Figure 16: Administrative measures to reduce the price of medicines 
2005 (Sep.) Administrative reduction of 6% in all 
medicines. Reduction of distribution 
margins to 26.6% 
2007 (Mar.) Administrative reduction of 6% in all 
medicines. Reduction of distribution 
margins to 25.12% 
2008 (Sep.) Administrative reduction of 30% in all 
GM 
2010 (Jul.) Average reduction of 7% in the price of 
branded medicines 
2010 (Aug.) Reduction of 20% to 35% in the price of 
some GM 
2010 (Oct.) Deduction of 6% in all medicines 
2012 (Jan.) Reduction of distribution margins to 
24.6% 
2012 (Apr.) Average reduction of 5.6% in the price of 
branded medicines 
2012 (May) Average reduction of 15.3% in the price of 
GM 
Source: OF 2012 
 
2.2.3.4 - Increase in GM Market 
The promotion of the GM market is being, for several years, one of the main goals of the 
drug politics in Portugal since the prescription and usage of these medicines reflect a saving 
potential to the patients and to the State (INFARMED, 2014). 
Since 2012, several measures have been being applied specifically to the GM segment with 
the purpose of increasing the quota of these medicines in the NHS market. All the measures 
aim to eliminate entry barriers to the market and decrease State expenditures.  
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Before 2005 the GM quota in Portugal was almost insignificant. However, this scenario 
changed drastically along the years and in the year of 2014, the GM quota in volume in 
Portugal was 36.5%, representing an increase of 15.4% since 2009 (INFARMED, 2015) 
(Figure 17). 
Figure 17: GM share evolution in the ambulatory market in Portugal, in percentage 
 
Source: INFARMED 2015 
Nonetheless, the quota of GM in volume and in value presents very different behaviours. 
Whereas the quota in volume is steadily increasing over the years, the quota in value shows 
an unsteady conduct, being always quite lower than the quota in volume. In 2014, the GM 
market presented a volume quota of 36,5%, while the one in value was 17,3% inferior. This 
situation reproduces the problematic of the enormous cut on medicine´s prices 
(INFARMED, 2015). 
 
2.2.4 – Sector´s Current Situation 
All the changes that occurred in the past years put the community pharmacy in a delicate 
situation. According to ANF, in May 2015 a fifth of Portuguese pharmacies were in a 
situation of insolvency or pawn. Between December 2012 and April 2015, there was an 
increase of 190.2% (61 to 177) in insolvencies and an increase of 88.1% (180 to 335) in 
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According to a study conducted by Antão, A.A. & Grenha C.M. (2014), the year 2012 
presented the pharmacy sector, for the first time, with a negative average net income 
(Figure 18). 
Figure 18: Income Statement of pharmacies in Portugal (average) 
Income Statement Average (1) 
Operational Income 35.052 
Net Operational Income 16.086 
EBIT 1.673 
Net Income -3757 
Source: Oliveira Reis e Associados, Aveiro University, 2012 
(1) The average refers to a medium value among the different levels of pharmacies 
according to their facturation.    
 
The study states that, on average, the community pharmacy in Portugal, presented a net 
income of -3.757 euros in 2012 and according to projections made to the year of 2013, this 
value decreased to -8.703 euros (Figure 19). 
 
Figure 19: Income Statement of pharmacies in Portugal (forecast)  
Income Statement Average (1) 
Operational Income 29.257 
Net Operational Income 10.290 
EBIT -4.122 
Net Income -8.703 
Source: Oliveira Reis e Associados, Aveiro University, 2012 
(1) The average refers to a medium value among the different levels of pharmacies 




Another situation that hampers the health of Portuguese pharmacies is the margins applied 
to medicines. These margins are one of the lowest in Europe, being only overcome by 
Romania (Lusa, 2015). 
 
Figure 20: Maximum margin of commercialization for reimbursed and non-
reimbursed medicines, ex-factory price as a base for calculation 
<5 5.58% plus 0.63 
5.01 to 7 5.51% plus 1.31 
7.01 to 10 5.36% plus 1.79 
10.01 to 20 5.05% plus 2.80 
20.01 to 50 4.49% plus 5.32 
>50 2.66% plus 8.28 
Source: (Health Ministry, DL 19/2014, 5 de Fevereiro 2014) 
 
2.2.5 - Tendencies and Strategies in the Sector: 
Facing the current situation of the sector, pharmacies need to take some actions in order to 
invert the current market scenario.  
One of the main tendencies is to create synergies and constitute pharmacy groups, 
following this way a reality that already exists in other markets such as United Kingdom.   
In the former years, pharmacies are forming groups in order to achieve synergies related 
with purchases, meaning best commercial conditions (Farmácia Distribuição, 2013). Apart 
from the economic advantages that come from aggregated purchases and operating cost 
optimization, these groups also create an umbrella brand that is common to the pharmacies 
that join them. This brand is a strong marketing tool to create brand awareness which is 
vital to promoting commodity-related products or services. Pharmacies may appear to offer 
similar products and brand recognition can be a way of differentiation and, in fact, 
brand/chain is considered to be the second most important reason why a client chooses a 




Another major tendency is the development of new areas of professional intervention such 
as nutrition services as well as social activities to support the population.  
In the action of selling a medicine, the price component will have less importance. In this 
action, the service component that is associated with the sale of the product will have more 
significance (Costa, 2012). 
In this service are included actions such as supplementary advisory in case of first dose, 
explanation on how to use therapeutic devices, identification of polymedicated patients to 
verify possible adverse reactions, preparation of individualized therapy, among others.  
The errors in administration of medicines or the lack of adherence to the therapy are 
responsible for the increase in the probability of treatment failure, avoidable complications, 
increase in health expenditures and increase in mortality. In Portugal, 43.000 patients enter 
in the hospital every year with complications from medicines that are considered avoidable. 
Between 15% and 40% of people who are more than 65 years old and enter in the hospital, 
is due to adverse reactions to medicines or lack of adherence to therapy (Grupo Holon, 
2013). 
Lastly, the areas of Marketing, Human Resources Management, Communication and 
Behavioural Phycology are becoming more important and crucial to form multidisciplinary 
teams that are more prepared to help the clients in the best way possible (Aguiar, 2012)  
The Community Pharmacy is a small and medium enterprise and, therefore, needs to focus 
in these areas in order to sustain the business and arise from the difficulties that the sector 
faces with a new force and image.  
Lastly, quality of service has to become a key concern. In an era where the service 
performed by the pharmacist is becoming more and more relevant, the quality of this should 
be considered a main focus to the company. In order to access the quality of care a 
framework can be used to ease the process. The Donabedian Model is a health care 
framework that describes the quality of health services in three different categories: 
structures, processes and outcomes. The first category refers to the physical and 
organizational aspects of health care settings (e.g. facilities, staff, equipment, operational 
and financial processes). Secondly, the processes refer to the transactions between patients 
and health providers and they appear in the middle of the diagram since they rely in the 
structures to provide resources for participants to carry out health activities (e.g. diagnosis, 
30 
 
treatment, preventive care, patient education). Finally, the outcomes stand for the effect of 
healthcare in the patient or population (e.g. health status, behaviour, knowledge, patient 
satisfaction). This framework was designed to be flexible for application in diverse health 
care settings (Donabedian, 1982). 
Figure 21: The Donabedian Model 
 
Source: Donabedian, 1982 
 “Pharmacists will need to gradually shift patients ‘perception from dispensers to providers 
of healthcare services and trusted clinical advice. Independent pharmacies as we know 


















Chapter 3 - Case Study 
 
3.1 - Introduction 
Grupo Holon is a national network of independent and autonomous pharmacies that appear 
in the market as a result of the legislative changes that occurred in the Portuguese scenario 
over the past years. After 2005 the community pharmacy in Portugal faced major 
alterations and that was the trigger for Pedro Pinto and his partner Diogo Cruz to start this 
project. As Pedro stated: “The challenges that the Portuguese pharmacy has been facing 
can be seen as threats but they also present opportunities to evolve and transform.” 
After observing how the market was structured in other countries, Pedro started to realize 
that there was a need for a change in Portugal and now was the best time for that. 
Pedro and Diogo were friends for a long time and both owned pharmacies in the country, 
Pedro four and Diogo two.  
However, soon they realized that only six pharmacies were not enough to form a strong 
position in the market and to achieve economies of scale. In order to do so they had to be 
at least ten times bigger, which led to the goal of reaching 60 pharmacies in order to 
implement their vision. To be able to achieve that number they used their network from the 
Pharmacy University where they had both studied. They started to contact friends they 
knew also had family pharmacies in order to increase the number of establishments in the 
group.  
That was the beginning of a group that nowadays counts with 372 pharmacies in Portugal 
and a 13% share in the market. 
 
3.2 -Mission and Values 
Grupo Holon is a network of pharmacies that operate under the same image and brand.  
The group was born in 2008 in order to materialize a project that started two years before 
with 60 pharmacies, two pharmaceuticals and a spirit of mutual help towards the sector of 
pharmacies in Portugal. 
Through the creation of this entity, Grupo Holon aims to develop a brand that focus on 
offering an excellent service to the community, based on an innovative and viable model.  
The core values of the group are: 
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 People - people are the most important resource and for that reason Grupo Holon 
tries to serve in the best way possible their clients, offering the best, most efficient 
and safest treatment and follow up.  
 Experience – with a valuable know-how, their clients can easily access a health 
service of quality and efficiency. 
 Rigor – in the pharmacies of Grupo Holon, the client can expect efficiency and 
accuracy. 
 Complicity – all the elements in the project are together and work together to get 
the best results. 
 Easy Going – in Grupo Holon is important to have a good mood and always show 
a smile in the face to the customer. 
 Open mind – Grupo Holon is a pioneer and innovative project in Portugal. It is 
fundamental to keep always an open mind to new ideas, projects and opinions in 
order to achieve success. 
 
3.3 - Value Proposition 
The two main objectives and benefits of the creation of this group were: 
 Identification of new clinical cases  
 Adherence to therapy  
The first objective is related to the identification of a disease or some factors that are more 
propitious to conduct to a future disease.  
This identification can be made by the pharmacist in the pharmacy when the patient meets 
him to ask for technical opinion about his symptoms or it can be made in the community 
by health screening promoted by the group or going to schools and other places in order to 
sensitize the community. 
The second objective concerns the good usage of medical devices or medication. The 
pharmacist has the role of explaining to the customer how the device or medication should 
be used in order to avoid wrong usage that can cause serious complications or avoid the 
patient to stop using it due to a lack of knowledge. The pharmacist also provides 
information about the wrong usage of medicines as adverse reactions or other 




These two main goals can only be achieved if the pharmacist is free to perform the activities 
that can only be made by him with the technological knowledge necessary.  
In order to release these professionals to conduct the activities that can add more value to 
the pharmacy and be perceived as more relevant by the clients, Grupo Holon decided to 
centralize the back office activities and some activities of front office.  
Beyond these goals that can directly affect and be perceived by the customer, the big 
purpose of the creation of this group is to modify a sector that in Portugal is very 
conservative and can be more innovative, attractive and improve the quality of service. 
Another major objective is to change the perception that people have about pharmacies, 
looking at it as just a logistics mean to get their medication. The goal is to change this 
mentality in the community and show to people that the pharmacy is a place of trust and 
technical knowledge where the customer can ask for advices and opinion with qualified 
health staff.  
 
3.4 - Operation Management Model 
Grupo Holon appear in the Portuguese market with a new concept of community pharmacy: 
modern, dynamic, professional and complete.  
The model that is proposed by Holon takes into consideration the peculiarities of every 
pharmacy and bases is alterations in operational and functional models in order to make 
those pharmacies more competitive in the market. 
 Strategic Cooperation among pharmacies: 
The model of operational management is based on the cooperation among the pharmacies 
that belong to the group by sharing resources, creating synergies, optimizing organization 
and functionality, optimizing purchases and potentiating sells, sharing know-how, sharing 
a common brand and image and promoting customer loyalty.  
 Centralization: 
In the Holon concept, all the back office activities should be centralized in order to release 
resources responsible to add value to the business. The implementation of a shared services 
central is also an important way of reducing operational costs of pharmacies. It also 


























communication plans and in strategic development of campaigns and their showcase 
design.    
When a pharmacy opens its doors for the first time, it starts to operate according to all 
Holon standards and regulations. However, when a pharmacy already exists in the market 
and joins the group, the rebranding process is phased and the pharmacy continues to operate 
under its original name stating it is operated by Grupo Holon until it modifies everything 
and operates as the other pharmacies in the group. Although this method helps the owners 
of pharmacies to make decisions and take actions in their own pace, currently the number 
of pharmacies that operates under the name “Farmácia Holon” is just 26, which represents 
7% of the total universe. 
To help in this process, Holon gives to all the pharmacies among the group a set of 
protocols for pharmacist advice in order to standardize rules and procedures to better 
service the community.  
 
3.7 - Physical Space 
Considering the market requirements, Grupo Holon introduced a new concept of innovative 
and sophisticated pharmacy space. The pharmacy presents defined areas segmented by 
products so the customer can easily find what they need (Exhibit 1). 
The group offers the possibility of having a personalized treatment in a particular and 
individualized counter if that is the client desire. On the other hand, it also offers an 
“express” counter for the clients that look for a faster treatment. 
In addition, the pharmacies also have cabinets to provide the specialized services. 
The layout of the pharmacy should comply with the vision of the company and transmits a 








3.8 - The Brand 
In Grupo Holon, all the pharmacies operate under the name of the company, have the same 
typography, rules and communication approach. The main objective is to strengthen the 
name of the group in the market. As Pedro Pinto stated: “We are not a group of pharmacies 
but a brand of pharmacy”. 
 The Name 
The name of the group comes from the Greek word Holon that means something as a whole 
and, simultaneously as a part of something bigger. Besides the meaning fitting perfectly 
the concept of the group, the choice of a foreigner word was also considered since in the 
Portuguese market the use of foreigner words as the name of a brand is considered to attract 
more customers. 
 The Colour Scheme 
The image of Grupo Holon has two main colours: white and purple.  
The purple colour is the international pharmacy colour which makes the group more 
innovative compared to the other pharmacies in Portugal that adopted the green colour and 
at the same time makes the pharmacies of the group stand out in the market.  
The white colour was chosen to give a clinical aspect, transmitting the idea of care to their 
customers and an image of professionalism and knowledge, allowing their customers to 
trust the pharmacies and their services. 
 The frontage 
The frontage of the pharmacy is the first contact between the customer and the store and, 
therefore one of the best places to communicate the brand and image of the company. The 
image of the group is also made by the window shops that have the same configuration and 
the same highlighted campaigns in all the locations. 
 
3.9 - Category Segmentation 
The segmentation of products into categories and sub-categories is a differentiator point of 
Grupo Holon pharmacies. This segmentation helps the customer finding what he needs 




3.10 - Products 
The products that a traditional pharmacy sells are normally segmented into three categories: 
PM, NPM and Health/Wellness products. 
In Farmácias Holon the PM segment represents 72% of sales which means the biggest slice. 
However, this is the segment that presents the lowest margins. The NPM segment has a 
weight of 12% and the Health/Beauty segment of 16%.   
Figure 25: Weight of Sales in Holon Pharmacies  
 
Source: Reunião Farmácias Holon, 2016 
 Owned Branded Product 
Holon believes that in order to be more complete it should propose a complementary offer 
that includes services and products and it was following that logic that it decided to launch 
its own brand of products in 2009. These products are the result of Holon R&D and a 























For the next year, the group intends to increase the number of pharmacies that provide 
services to 160, the pharmacies that participate in projects to 300, the participation in 
congresses to 6 and intend to appear in 2 scientific magazines. 
3.12 - Quality 
In 2014, Holon pharmacies registered a satisfaction rate of 95% and a loyalty rate of 51%. 
The group also uses a mystery client to rank their performance levels that presented a value 
of 58% in 2011 and increased to 80.9% in 2015. 
3.13 - The Future 
Although the different changes in the Portuguese market present risks and threats for 
pharmacies, the same can be seen as opportunities to gather efforts and from that arise 
with more developed and organized businesses in order to satisfy in a better way the 
needs of the customers. This is a process that is still in the beginning, considering that 
customers are becoming more informed and more demanding, challenging pharmacies 
to always keep up with them and present innovative solutions.  
The group define itself as “the future of the pharmaceutical service” and has been making 
efforts to achieve that goal. However, in order to do that, it should continue asking itself: 
“How can we be seen as a part of the health system, instead of just a medicine´s provider? 
How can we increase our brand awareness? How can we actually become the future of 












Exhibit 1 – Holon Physical Space  
 
Exhibit 2 – Holon Category Segmentation
 




Chapter 4 – Teaching Notes 
4.1 - Case Summary 
Grupo Holon is a network of independent pharmacies that operate under the same image 
and brand. The group appears in the Portuguese market as a consequence of several changes 
that affected negatively the community pharmacy sector.  
The main goal of the group is to change the perception of the pharmacy as just a medicine 
supplier and provide to their customers value added services that have the objective of 
identifying new clinical cases and promote the adherence to therapy. 
The group centralizes its back office activities which enables the pharmacist to perform the 
activities that actually bring value to the community pharmacy. This centralization also 
allows shared resources and know-how, synergies and economies of scale, among others.  
The group also focus its efforts in conducting projects among the community that aim to 
create awareness to several issues as well as reach people that normally would not go to 
the pharmacy.   
4.2 - Learning Objectives 
This case study was designed for students who have a special interest in the health sector 
since it gives the student the opportunity to understand the evolution of the community 
pharmacy sector and its consequences in the market. It is also designed for people 
interested in strategy since it enables the student to perform a strategic analysis. 
The main goals of the case study are: 
 Provide students with knowledge about the healthcare sector in Portugal and its 
evolution 
 Create awareness about community pharmacy in Portugal, its importance and its 
market situation 
 Enable students to apply strategic analysis and frameworks as well as develop new 
knowledge about healthcare strategic models 




4.3 - Teaching Questions 
 
1- Comment the market reasons that were in the origin of the appearance of 
Grupo Holon. 
In order to enumerate the conditions that provided a change in the sector and, therefore, the 
appearance of the group in the Portuguese market, the student can produce a PEST 
analysis. 
Among the relevant political factors it is worth to highlight that this is a sector heavily 
regulated by the State and, therefore, strongly affected by these changes. 
The main factors that influence the activities of the group are the political changes in the 
laws of the sector. The property liberalization brought the end of the exclusive ownership 
of pharmacies by pharmacists. With this alteration every single person or entity is allowed 
to acquire a community pharmacy, contributing to the increase of the number of 
establishments in the market. 
The approval of a law that enables the sale of NPM outside of pharmacies also contributed 
to a change in the market scenario since this situation creates a new competitive 
environment with the number of NPM selling points increasing in the Portuguese market. 
The promotion of GM market is also one of the main focus in health politics in Portugal. 
This market has been increasing over the years with the support of governmental measures 
in order to increase their quota. 
Another political measure taken in this sector was the progressive reduction of medicine´s 
prices by administrative cuts and introduction of current reimbursed model. 
Regarding the economic factors, it is worth to highlight the reduction in expenditures on 
healthcare in Portugal that have been decreasing since 2009 (Figure 1). It also observable 
that the specific expense in pharmaceutical products have been decreasing (Figure 4) as 
well as the value of pharmaceutical market (Figure 5). 
45 
 
Another economic factor to take into account, is the reduction in the average household 
disposable income, which affects directly the purchasing power of customers (Figure 13). 
One of the most relevant social factors that influences this sector, consists on the aging 
tendency of the Portuguese population (Annex 1). The segment of more than 65 years old 
people is the segment that consumes more medicines and the one where is verified the 
highest number of issues in their usage. 
The technological factor that can be considered in this case as relevant for the group is the 
opportunity of companies to develop and produce their own line of products in the health 
sector by investing in R&D and establishing partnerships with laboratories. 
Figure 28: PEST Analysis Holon 
Political Factors  Property Liberalization 
 Sale of NPM outside of 
Pharmacies 
 Promotion of GM market 
 Reduction of medicine´s price 
Economic Factors  Reduction of expenditures on 
healthcare 
 Decrease in expenses in 
pharmaceutical products 
 Decrease in pharmaceutical 
market value 
 Reduction in average household 
disposable income  
Social Factors  Aging tendency of Portuguese 
population 
 
Technological Factors  Development of product´s lines 




1- Identify the current internal and external factors that define the 
performance of Grupo Holon. 
 
Using a SWOT analysis it is possible to examine the current strengths and weaknesses of 
the group, as well as the market opportunities and threatens, performing an analysis of 
internal and external factors. 
Considering the strengths of the group, it allows their pharmacies to achieve certain 
advantages that independent ones difficultly could get as economies of scale, share of 
know-how, centralization of back office activities, creation of synergies and share of 
resources. 
The group also has its own brand of products and soon will start to have their own NPM 
line. Independent pharmacies do not have conditions do develop their own brand so this 
presents an advantage.  
By belonging to the group, pharmacies also have the opportunity to have marketing plans 
and community projects that bring brand awareness to the group, increasing its recognition 
and benefits in the Portuguese market.  
The rebranding process is also adaptable to every pharmacy needs and desires, enabling 
the owners to maintain their freedom and autonomy until certain levels. 
Due to the dimension that pharmacies get by joining the group, several of them can benefit 
from providing their clients with additional services as appointments and screenings as well 
as community projects by which they can reach people that normally would not go the 
pharmacy.  
Finally, one of the main advantages that also represents a sum up of all the benefits of 
centralizing activities, is a pharmacist that can develop their job in a more efficient way 
and representing more benefits to the customer.  The pharmacist gains time to perform with 




Although presenting several advantages, the group still has some weaknesses to improve.  
However the group holds 372 pharmacies, only 129 offer to their clients specialized 
services, representing still only 34.6% of the total universe. Among the pharmacies that 
carry out projects this number drops to 118, representing 31.7%. These are values that have 
space for improvement and are in the plan of actions to develop during 2016. 
Another point of improvement is the fact that only 7% of the pharmacies operate under the 
name “Farmácia Holon”. In order to create a brand that is recognized in the market, the 
name is extremely important and although the other pharmacies have the same frontage 
and signalize that they operate under Grupo Holon, it is not the same output than having 
the majority of the pharmacies using the same name. Although the phased rebranding 
process is positive for the owners of the pharmacies and present advantages, also present 
the advantage of postponing the creation of a recognized brand. 
Regarding opportunities that the market offers, it is observable that the constitution of 
pharmacy groups is a growing tendency. This situation occurs due to all the changes that 
happened in the sector: selling of NPM outside of pharmacies, property liberalization, 
increase of GM market and medicine´s price reduction.  All these changes affected 
negatively the community pharmacy but they also present opportunities to evolve and 
modify a market that has been conservative. These factors enable pharmacies to develop 
new strategies and become more innovative, creating groups to help achieving their 
objectives and creating synergies. 
On the threats side, the health market where the community pharmacy is inserted is heavily 
regulated and, therefore, is highly dependent on government politics. These politics can 








Figure 29: SWOT Analysis Holon 
 
2- Avedis Donabedian developed a model to access the quality of care in 
health services. Can you apply it to the case of Grupo Holon? 
The Donabedian Model (Donabedian, 1982) is a flexible framework that can be applied 
to diverse health care scenarios. In order to analyse the quality of care of Grupo Holon, it 
should be considered three categories: structures, processes and outcomes. 
In the first category, the physical aspect of the pharmacies have to be considered. As the 
case stipulates, Holon pharmacies present a sophisticated and innovative pharmacy space, 
presenting areas that are segmented by products, making the search for a product an easy 
process to the customer. 
Considering the areas to provide pharmacy services, Holon pharmacies provide their 
customers with three different spaces according to their needs: an “express” counter for 
customers that seek for a faster treatment, an individualized counter for customers that 
desire a more personalized treatment and cabinets to provide specialized services. All the 
design of the physical space was created to transmit a feeling of credibility and clinical 
space. 
Strenghts
- Centralization of activities (economies of scale, 
share of resources and know-how, synergies)
- Own line of products
- Marketing and community awareness
- Sevices (portfolio and advisory)
- The role of the pharmacist
Weaknesses
- Number of pharmacies operating under the exact 
same name (brand awareness)
- Number of pharmacies with service offers and 
project participation 
Opportunities
- Changes in the market that increase the need for 
groups´ creation and innovative strategic approaches
Threats
- Heavily regulated market
- High dependence on Government politics
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In terms of operational processes, the group has their back office activities centralized 
which enables the pharmacists to have more time to perform their added value activities. 
These pharmacists represent the staff of Holon pharmacies and one of the key assets of the 
group having the necessary knowledge to provide added value services to their customers. 
In the second category of the present model, it is supposed to identify the processes between 
health provider and customer. 
Grupo Holon presents two main objectives when interacting with their customers: 
identification of new clinical cases and adherence to therapy. The first one is linked with 
the diagnosis process whereas the second one is linked with preventive care and patient 
education. 
The group also offers to their customers a wide range of services such as nutrition 
appointments or diabetic foot appointments that have the purpose of diagnosis and 
treatment. 
Another process to consider, that is one of the differentiators of the group is, is the 
community awareness projects that can be performed as workshops, health fairies and 
screening. These activities have the main goal of patient education and preventive care but 
also diagnosis through the screenings for instance. 
Finally the outcomes of the group show a satisfaction rate of 95% and a loyalty rate of 51% 
in 2014. The mystery client method used by the group also evaluated it in 80.9% in 2015, 
showing an improvement of 22.9% since 2011. These values represent the average 
customer satisfaction with Holon services and performances. 
4 - “The pharmaceutical service of the future.” Comment this sentence 
highlighting how the group can achieve this objective. 
This is an open question to analyse the student´s critical thinking about the future vision 
and strategy of the group.  
Grupo Holon identified a need for a change in the community pharmacy in Portugal. In the 
sequence of that, it appeared in the market with the goal of changing the perception that 
people have about pharmacies being just a drug dispenser. 
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In order to do so, the group attempts to offer to their customers benefits that they believe 
will not find in other pharmacies. These benefits include: 
 Identification of new clinical cases by the pharmacist directly in the pharmacy or 
through screenings among the community 
 Adherence to therapy through the explanation of pharmacists about wrong usage of 
medicines or medical devices as well as detection of forgetfulness 
 Specialized services as nutrition or pharmaceutical appointments 
 A wide range of their own branded products 
 Community awareness projects where the group provides knowledge and 
awareness 
The group introduces, this way, news in the sector that contribute for the customer to look 
at the pharmacy as a place of trust and health advisory. However, these advances are only 
possible due to the centralization of back office activities that, among other advantages, 
allows the pharmacist to perform added value activities. 
In order to develop an innovative pharmaceutical service and reach the proposed objectives 
for the future, the group should focus on some points: 
 Increase brand awareness – the brand is a fundamental marketing tool and crucial 
to promote products and services. It is what creates visibility and one of the main 
reasons why a customer chooses a specific service or product. This brand awareness 
can be attainable trough the intensification of performance of community projects 
and activities and through a bigger visibility of the group among the general public 
that can be achieved by developing advertising campaigns in the television or 
magazines. The window shops are also a good tool to advertise Holon products, 
services and campaigns. 
The phased rebranding process has multiple advantages but at the same time 
postpone the creation of a common image. This process can and should exist but 
maybe with some limitations that would not conduct to just 7% of pharmacies 
operating under the name “Farmácia Holon”. 
 
 Develop Services and Products – the development of services as the ones already 
provided by Holon aim to differentiate the group at the same time as provide 
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benefits to the community. In order to increase the adherence to these services, their 
marketing is extremely important. Spreading the idea of community pharmacy as a 
health space helps the customer to seek for these kind of services. It is also 
important to innovate and explore new services to add to the ones already existing 
as for example vision appointments and sale of glasses and contact lenses. The 
portfolio of Holon products is also a source of recognition and should continue to 
be an investment target. 
 
 Increase the importance of the Pharmacist – the pharmacist is the most important 
asset of the pharmacy. In order to develop a “service of the future”, the highlight 
should be on the role played by the pharmacist since they have the knowledge to 
provide health advisory and health services. In order to enable even more the 
pharmacist to perform their activities, complementary areas should be taught to 
them as marketing, human resources, strategy or communication. Having the best 
team is a key factor for any business and giving these tools to pharmacist will help 
developing the pharmacy activity and will potentiate the change in people´s minds 












Chapter 5 – Conclusion, Limitations and Future Research 
5.1 - Conclusion 
After analysing the factors that contributed to the current situation of community 
pharmacies in Portugal (RQ1), it is verified that the healthcare sector in the country has 
been facing some changes during the former years. Expenditures on health and 
pharmaceutical goods have been decreasing, which contributes to a devaluation of around 
21% in value of the pharmaceutical market.   
The community pharmacy itself has been witnessing an increase in the number of 
establishments. However, the sale of PM, that was always the core business of any 
community pharmacy, decreased in value almost 30% since 2009. This situation is the 
reflection of several changes in the sector that brought the community pharmacy to a 
struggle in a market where a fifth of pharmacies are in insolvency process.  
Facing this situation, some strategies have to be taken in order to change it (RQ2): 
 The role of the pharmacist has to start to gain more importance since he is the 
responsible for providing added value services and, therefore, the responsible to 
provide good quality services, which is becoming a key concern.  
 The creation of groups of pharmacies is crucial in order to form a network of shared 
knowledge and shared benefits such as centralization of activities and economies 
of scale. 
 The importance of extend the pharmacy activities in order to provide other services 
that go beyond the simply sale of medicines. These services can take the form of 
specialized services or advisory in the action of selling the medicine.  
 The development of new areas of concern such as marketing and communication, 
in order to build a stronger and multifaceted business. 
 The importance of creating a brand and have a common image and presence in the 
market. 
Grupo Holon took advantage of all the difficulties in the market and used them as 
opportunities, creating a network of pharmacies that offer to their customers´ added value 
services. The group uses its centralization system to release the pharmacist to perform 
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advisory services, specialized services, community awareness and identification of new 
cases. The group has been able to strengthen its position in the market, reaching the 
community and achieving high levels of satisfaction.  
However, it is important to deepen the efforts in creating brand awareness, since this can 
be a tool to promote Holon services and products. It is also important to continue to expand 
its portfolio of services and projects that aim to contribute to a shift in the customer´s mind, 
creating the vision that the community pharmacy is more than just a medicine supplier; it 
is a part of the health system and a clinical space of trust and knowledge. To do so is also 
important to continue to develop the role and image of the pharmacist.  
 
5.2 - Limitations 
Regarding the literature review, there were some limitations in finding some data about 
more recent years, as the case of the income statements of community pharmacies or 
average household income for instance. It was also difficult to find academic literature 
about the subject, the main sources of information being institutional reports and 
legislation. All the tendencies presented affect directly the strategic performance of 
pharmacies, being excluded the ones which are not linked with strategic issues.  
Concerning the case study, financial data was not provided so no financial analysis was 
performed during this dissertation, which could have been useful in order to analyse the 
evolution of the group´s revenues.  
 
5.3 - Future Research 
For future research regarding the company, it could be useful to study the impact that the 
Holon brand has in the general public in order to know if the group is achieving brand 
awareness and in negative case, analyse the possible future actions to take. It could be also 
useful to study which services are more valuable for the customer in order to focus efforts 
in those ones. 
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In terms of the sector itself, it could be useful to conduct a study to analyse the reasons 
behind the increase in the number of NPM establishments. Considering that the sales of 
these medicines did not increase that much, we can be facing a change in consumer´s habits 
that now purchase the same amount of the product but in a different place. In this case, 
some other strategies should be taken into consideration in order to maintain the loyalty of 
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